{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T23:31:46Z","timestamp":1785540706122,"version":"3.56.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40265-025-02216-7","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T14:26:39Z","timestamp":1759415199000},"page":"1551-1563","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Current Treatment Landscape for Congenital Adrenal Hyperplasia"],"prefix":"10.1007","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7492-8288","authenticated-orcid":false,"given":"Joseph J.","family":"Tonge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7726-4299","authenticated-orcid":false,"given":"Irina","family":"Bacila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3402-4727","authenticated-orcid":false,"given":"Nils P.","family":"Krone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"key":"2216_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00136-7","author":"ES Husebye","year":"2021","unstructured":"Husebye ES, Pearce SH, Krone NP, K\u00e4mpe O. Adrenal insufficiency. Lancet. 2021. https:\/\/doi.org\/10.1016\/S0140-6736(21)00136-7.","journal-title":"Lancet"},{"key":"2216_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/FNBEH.2020.601939","volume":"14","author":"JA Sheng","year":"2021","unstructured":"Sheng JA, Bales NJ, Myers SA, Bautista AI, Roueinfar M, Hale TM, et\u00a0al. The hypothalamic\u2013pituitary\u2013adrenal axis: development, programming actions of hormones, and maternal\u2013fetal interactions. Front Behav Neurosci. 2021;14: 601939. https:\/\/doi.org\/10.3389\/FNBEH.2020.601939.","journal-title":"Front Behav Neurosci"},{"key":"2216_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/J.PHYSBEH.2016.11.014","volume":"178","author":"RL Spencer","year":"2017","unstructured":"Spencer RL, Deak T. A users guide to HPA axis research. Physiol Behav. 2017;178:43\u201365. https:\/\/doi.org\/10.1016\/J.PHYSBEH.2016.11.014.","journal-title":"Physiol Behav"},{"key":"2216_CR4","doi-asserted-by":"publisher","first-page":"T43","DOI":"10.1530\/JME-13-0238","volume":"52","author":"DA Lovejoy","year":"2014","unstructured":"Lovejoy DA, Chang BSW, Lovejoy NR, del Castillo J. Molecular evolution of GPCRS: CRH\/CRH receptors. J Mol Endocrinol. 2014;52:T43-60. https:\/\/doi.org\/10.1530\/JME-13-0238.","journal-title":"J Mol Endocrinol"},{"key":"2216_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/FNMOL.2018.00305\/PDF","volume":"11","author":"A Raftogianni","year":"2018","unstructured":"Raftogianni A, Roth LC, Garc\u00eda-Gonz\u00e1lez D, Bus T, K\u00fchne C, Monyer H, et\u00a0al. Deciphering the contributions of CRH receptors in the brain and pituitary to stress-induced inhibition of the reproductive axis. Front Mol Neurosci. 2018;11: 408224. https:\/\/doi.org\/10.3389\/FNMOL.2018.00305\/PDF.","journal-title":"Front Mol Neurosci"},{"key":"2216_CR6","doi-asserted-by":"publisher","first-page":"216","DOI":"10.18699\/VJ21.025","volume":"25","author":"EV Sukhareva","year":"2021","unstructured":"Sukhareva EV. The role of the corticotropin-releasing hormone and its receptors in the regulation of stress response. Vavilov J Genet Breed. 2021;25:216. https:\/\/doi.org\/10.18699\/VJ21.025.","journal-title":"Vavilov J Genet Breed"},{"key":"2216_CR7","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1002\/cphy.c140003","volume":"4","author":"F Spiga","year":"2014","unstructured":"Spiga F, Walker JJ, Terry JR, Lightman SL. HPA axis-rhythms. Compr Physiol. 2014;4:1273\u201398. https:\/\/doi.org\/10.1002\/cphy.c140003.","journal-title":"Compr Physiol"},{"key":"2216_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/NPP.2015.171","volume":"41","author":"BS McEwen","year":"2015","unstructured":"McEwen BS, Nasca C, Gray JD. Stress effects on neuronal structure: hippocampus, amygdala, and prefrontal cortex. Neuropsychopharmacology. 2015;41:3. https:\/\/doi.org\/10.1038\/NPP.2015.171.","journal-title":"Neuropsychopharmacology"},{"key":"2216_CR9","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.bbadis.2011.02.003","volume":"1812","author":"S Chung","year":"2011","unstructured":"Chung S, Son GH, Kim K. Circadian rhythm of adrenal glucocorticoid: Its regulation and clinical implications. Biochim Biophys Acta Mol Basis Dis. 2011;1812:581\u201391.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"2216_CR10","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000022621","volume":"99","author":"MI Butt","year":"2020","unstructured":"Butt MI, Alzuhayri N, Amer L, Riazuddin M, Aljamei H, Khan MS, et\u00a0al. Comparing the utility of 30- and 60-minute cortisol levels after the standard short synacthen test to determine adrenal insufficiency: a retrospective cross-sectional study. Medicine (Baltimore). 2020;99: e22621\u2013e22621. https:\/\/doi.org\/10.1097\/MD.0000000000022621.","journal-title":"Medicine (Baltimore)"},{"key":"2216_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S40101-022-00294-0","volume":"41","author":"SD Wong","year":"2022","unstructured":"Wong SD, Wright KP, Spencer RL, Vetter C, Hicks LM, Jenni OG, et\u00a0al. Development of the circadian system in early life: maternal and environmental factors. J Physiol Anthropol. 2022;41:1\u201313. https:\/\/doi.org\/10.1186\/S40101-022-00294-0.","journal-title":"J Physiol Anthropol"},{"key":"2216_CR12","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1053\/j.nainr.2005.09.002","volume":"5","author":"CA Elverson","year":"2005","unstructured":"Elverson CA, Wilson ME. Cortisol: circadian rhythm and response to a stressor. Newborn Infant Nurs Rev. 2005;5:159\u201369.","journal-title":"Newborn Infant Nurs Rev"},{"key":"2216_CR13","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0163-6383(02)00141-8","volume":"25","author":"C de Weerth","year":"2002","unstructured":"de Weerth C, van Geert P. A longitudinal study of basal cortisol in infants: intra-individual variability, circadian rhythm and developmental trends. Infant Behav Dev. 2002;25:375\u201398.","journal-title":"Infant Behav Dev"},{"key":"2216_CR14","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/J.BIOPHA.2017.07.091","volume":"94","author":"S Patel","year":"2017","unstructured":"Patel S, Rauf A, Khan H, Abu-Izneid T. Renin\u2013angiotensin\u2013aldosterone (RAAS): the ubiquitous system for homeostasis and pathologies. Biomed Pharmacother. 2017;94:317\u201325. https:\/\/doi.org\/10.1016\/J.BIOPHA.2017.07.091.","journal-title":"Biomed Pharmacother"},{"key":"2216_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/FENDO.2016.00072","volume":"7","author":"N El Ghorayeb","year":"2016","unstructured":"El Ghorayeb N, Bourdeau I, Lacroix A. Role of ACTH and other hormones in the regulation of aldosterone production in primary aldosteronism. Front Endocrinol (Lausanne). 2016;7: 72. https:\/\/doi.org\/10.3389\/FENDO.2016.00072.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2216_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1239492","volume":"14","author":"S Gambaryan","year":"2023","unstructured":"Gambaryan S, Mohagaonkar S, Nikolaev VO. Regulation of the renin\u2013angiotensin\u2013aldosterone system by cyclic nucleotides and phosphodiesterases. Front Endocrinol (Lausanne). 2023;14: 1239492.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2216_CR17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1210\/ENDREV\/BNAB016","volume":"43","author":"HLC van der Grinten","year":"2022","unstructured":"van der Grinten HLC, Speiser PW, Faisal Ahmed S, Arlt W, Auchus RJ, Falhammar H, et\u00a0al. Congenital adrenal hyperplasia-current insights in pathophysiology, diagnostics, and management. Endocr Rev. 2022;43:91\u2013159. https:\/\/doi.org\/10.1210\/ENDREV\/BNAB016.","journal-title":"Endocr Rev"},{"key":"2216_CR18","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1210\/JC.2009-2631","volume":"95","author":"PW Speiser","year":"2010","unstructured":"Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP, et\u00a0al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95:4133\u201360. https:\/\/doi.org\/10.1210\/JC.2009-2631.","journal-title":"J Clin Endocrinol Metab"},{"key":"2216_CR19","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S0140-6736(22)01330-7","volume":"401","author":"MK Auer","year":"2023","unstructured":"Auer MK, Nordenstr\u00f6m A, Lajic S, Reisch N. Congenital adrenal hyperplasia. Lancet. 2023;401:227\u201344. https:\/\/doi.org\/10.1016\/S0140-6736(22)01330-7.","journal-title":"Lancet"},{"key":"2216_CR20","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/S11154-022-09717-W","volume":"23","author":"MAM Schr\u00f6der","year":"2022","unstructured":"Schr\u00f6der MAM, Claahsen-van der Grinten HL. Novel treatments for congenital adrenal hyperplasia. Rev Endocr Metab Disord. 2022;23:631\u201345. https:\/\/doi.org\/10.1007\/S11154-022-09717-W.","journal-title":"Rev Endocr Metab Disord"},{"key":"2216_CR21","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1210\/JC.2018-01865","volume":"103","author":"PW Speiser","year":"2018","unstructured":"Speiser PW, Arlt W, Auchus RJ, Baskin LS, Conway GS, Merke DP, et\u00a0al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2018;103:4043\u201388. https:\/\/doi.org\/10.1210\/JC.2018-01865.","journal-title":"J Clin Endocrinol Metab"},{"key":"2216_CR22","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1530\/EJE-13-0128","volume":"168","author":"TS Han","year":"2013","unstructured":"Han TS, Krone N, Willis DS, Conway GS, Hahner S, Rees DA, et\u00a0al. Quality of life in adults with congenital adrenal hyperplasia relates to glucocorticoid treatment, adiposity and insulin resistance: United Kingdom Congenital Adrenal Hyperplasia Adult Study Executive (CaHASE). Eur J Endocrinol. 2013;168:887\u201393. https:\/\/doi.org\/10.1530\/EJE-13-0128.","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"2216_CR23","doi-asserted-by":"publisher","first-page":"5110","DOI":"10.1210\/JC.2010-0917","volume":"95","author":"W Arlt","year":"2010","unstructured":"Arlt W, Willis DS, Wild SH, Krone N, Doherty EJ, Hahner S, et\u00a0al. Health status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients. J Clin Endocrinol Metab. 2010;95(11):5110\u201321. https:\/\/doi.org\/10.1210\/JC.2010-0917.","journal-title":"J Clin Endocrinol Metab"},{"key":"2216_CR24","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1210\/CLINEM\/DGAE068","volume":"109","author":"S Gunawardana","year":"2024","unstructured":"Gunawardana S, Jayarajah U, Ahmed SF, Seneviratne SN. Health-related quality of life in children and adolescents with congenital adrenal hyperplasia: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2024;109:1618\u201329. https:\/\/doi.org\/10.1210\/CLINEM\/DGAE068.","journal-title":"J Clin Endocrinol Metab"},{"key":"2216_CR25","doi-asserted-by":"publisher","first-page":"E336","DOI":"10.1210\/CLINEM\/DGAD405","volume":"109","author":"NR Lawrence","year":"2023","unstructured":"Lawrence NR, Bacila I, Dawson J, Mahdi S, Alvi S, Cheetham TD, et\u00a0al. Quality of life in children and young people with congenital adrenal hyperplasia\u2014UK nationwide multicenter assessment. J Clin Endocrinol Metab. 2023;109:E336\u201346. https:\/\/doi.org\/10.1210\/CLINEM\/DGAD405.","journal-title":"J Clin Endocrinol Metab"},{"key":"2216_CR26","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/CEN.14960","volume":"101","author":"IA Bacila","year":"2024","unstructured":"Bacila IA, Lawrence NR, Badrinath SG, Balagamage C, Krone NP. Biomarkers in congenital adrenal hyperplasia. Clin Endocrinol (Oxf). 2024;101:300\u201310. https:\/\/doi.org\/10.1111\/CEN.14960.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2216_CR27","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1530\/EJE-20-1249","volume":"184","author":"I Bacila","year":"2021","unstructured":"Bacila I, Freeman N, Daniel E, Sandrk M, Bryce J, Ali SR, et\u00a0al. International practice of corticosteroid replacement therapy in congenital adrenal hyperplasia: data from the i-CAH registry. Eur J Endocrinol. 2021;184:553\u201363. https:\/\/doi.org\/10.1530\/EJE-20-1249.","journal-title":"Eur J Endocrinol"},{"key":"2216_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13023-017-0603-7\/FIGURES\/6","volume":"12","author":"M Kourime","year":"2017","unstructured":"Kourime M, Bryce J, Jiang J, Nixon R, Rodie M, Ahmed SF. An assessment of the quality of the I-DSD and the I-CAH registries - International registries for rare conditions affecting sex development. Orphanet J Rare Dis. 2017;12:1\u201312. https:\/\/doi.org\/10.1186\/S13023-017-0603-7\/FIGURES\/6.","journal-title":"Orphanet J Rare Dis"},{"key":"2216_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/CEN.14961","author":"X Tseretopoulou","year":"2024","unstructured":"Tseretopoulou X, Bryce J, Chen M, McMillan M, Lucas-Herald AK, Ali SR, et\u00a0al. The I-CAH registry: a platform for international collaboration for improving knowledge and clinical care in congenital adrenal hyperplasia. Clin Endocrinol (Oxf). 2024. https:\/\/doi.org\/10.1111\/CEN.14961.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2216_CR30","unstructured":"International registries for rare conditions affecting sex development & maturation."},{"key":"2216_CR31","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1210\/JC.2012-2102","volume":"97","author":"GP Finkielstain","year":"2012","unstructured":"Finkielstain GP, Kim MS, Sinaii N, Nishitani M, Van Ryzin C, Hill SC, et\u00a0al. Clinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2012;97:4429\u201338. https:\/\/doi.org\/10.1210\/JC.2012-2102.","journal-title":"J Clin Endocrinol Metab"},{"key":"2216_CR32","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/S41574-022-00655-W","volume":"18","author":"A Mallappa","year":"2022","unstructured":"Mallappa A, Merke DP. Management challenges and therapeutic advances in congenital adrenal hyperplasia. Nat Rev Endocrinol. 2022;18:337\u201352. https:\/\/doi.org\/10.1038\/S41574-022-00655-W.","journal-title":"Nat Rev Endocrinol"},{"key":"2216_CR33","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1210\/JC.2014-1258","volume":"99","author":"RJ Auchus","year":"2014","unstructured":"Auchus RJ, Buschur EO, Chang AY, Hammer GD, Ramm C, Madrigal D, et\u00a0al. Abiraterone acetate to lower androgens in women with classic 21-hydroxylase deficiency. J Clin Endocrinol Metab. 2014;99:2763\u201370. https:\/\/doi.org\/10.1210\/JC.2014-1258.","journal-title":"J Clin Endocrinol Metab"},{"key":"2216_CR34","doi-asserted-by":"publisher","first-page":"4161","DOI":"10.1210\/JC.2009-2616","volume":"95","author":"K Muthusamy","year":"2010","unstructured":"Muthusamy K, Elamin MB, Smushkin G, Murad MH, Lampropulos JF, Elamin KB, et\u00a0al. Clinical review: adult height in patients with congenital adrenal hyperplasia: a systematic review and metaanalysis. J Clin Endocrinol Metab. 2010;95:4161\u201372. https:\/\/doi.org\/10.1210\/JC.2009-2616.","journal-title":"J Clin Endocrinol Metab"},{"key":"2216_CR35","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1067\/S0022-3476(03)00294-4","volume":"143","author":"Z Punthakee","year":"2003","unstructured":"Punthakee Z, Legault L, Polychronakos C. Prednisolone in the treatment of adrenal insufficiency: a re-evaluation of relative potency. J Pediatr. 2003;143:402\u20135. https:\/\/doi.org\/10.1067\/S0022-3476(03)00294-4.","journal-title":"J Pediatr"},{"key":"2216_CR36","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3345\/CEP.2024.01060","volume":"68","author":"P Wiromrat","year":"2024","unstructured":"Wiromrat P, Raruenrom Y, Namphaisan P, Wongsurawat N, Panamonta O, Pongchaiyakul C. Prednisolone impairs trabecular bone score changes in adolescents with 21-hydroxylase deficiency. Clin Exp Pediatr. 2024;68:238\u201346. https:\/\/doi.org\/10.3345\/CEP.2024.01060.","journal-title":"Clin Exp Pediatr."},{"key":"2216_CR37","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1210\/JC.2014-4060","volume":"100","author":"MJ Whitaker","year":"2015","unstructured":"Whitaker MJ, Spielmann S, Digweed D, Huatan H, Eckland D, Johnson TN, et\u00a0al. Development and testing in healthy adults of oral hydrocortisone granules with taste masking for the treatment of neonates and infants with adrenal insufficiency. J Clin Endocrinol Metab. 2015;100:1681\u20138. https:\/\/doi.org\/10.1210\/JC.2014-4060.","journal-title":"J Clin Endocrinol Metab"},{"key":"2216_CR38","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/CEN.13447","volume":"88","author":"U Neumann","year":"2018","unstructured":"Neumann U, Whitaker MJ, Wiegand S, Krude H, Porter J, Davies M, et\u00a0al. Absorption and tolerability of taste-masked hydrocortisone granules in neonates, infants and children under 6 years of age with adrenal insufficiency. Clin Endocrinol (Oxf). 2018;88:21\u20139. https:\/\/doi.org\/10.1111\/CEN.13447.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2216_CR39","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1210\/JS.2018-00380","volume":"3","author":"E Daniel","year":"2019","unstructured":"Daniel E, Digweed D, Quirke J, Voet B, Ross RJ, Davies M. Hydrocortisone granules are bioequivalent when sprinkled onto food or given directly on the tongue. J Endocr Soc. 2019;3:847\u201356. https:\/\/doi.org\/10.1210\/JS.2018-00380.","journal-title":"J Endocr Soc"},{"key":"2216_CR40","doi-asserted-by":"publisher","first-page":"E1433","DOI":"10.1210\/CLINEM\/DGAA626","volume":"106","author":"U Neumann","year":"2021","unstructured":"Neumann U, Braune K, Whitaker MJ, Wiegand S, Krude H, Porter J, et\u00a0al. A prospective study of children aged 0\u20138 years with CAH and adrenal insufficiency treated with hydrocortisone granules. J Clin Endocrinol Metab. 2021;106:E1433\u201340. https:\/\/doi.org\/10.1210\/CLINEM\/DGAA626.","journal-title":"J Clin Endocrinol Metab"},{"key":"2216_CR41","doi-asserted-by":"publisher","first-page":"S74","DOI":"10.1210\/CLINEM\/DGAE759","volume":"110","author":"K Sarafoglou","year":"2025","unstructured":"Sarafoglou K, Auchus RJ. Future directions in the management of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab. 2025;110:S74. https:\/\/doi.org\/10.1210\/CLINEM\/DGAE759.","journal-title":"J Clin Endocrinol Metab"},{"key":"2216_CR42","doi-asserted-by":"publisher","first-page":"E1729","DOI":"10.1210\/CLINEM\/DGAA071","volume":"105","author":"J Melin","year":"2020","unstructured":"Melin J, Parra-Guillen ZP, Michelet R, Truong T, Huisinga W, Hartung N, et\u00a0al. Pharmacokinetic\/pharmacodynamic evaluation of hydrocortisone therapy in pediatric patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2020;105:E1729\u201340. https:\/\/doi.org\/10.1210\/CLINEM\/DGAA071.","journal-title":"J Clin Endocrinol Metab"},{"key":"2216_CR43","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/CEN.13837","volume":"90","author":"R Dineen","year":"2019","unstructured":"Dineen R, Stewart PM, Sherlock M. Factors impacting on the action of glucocorticoids in patients receiving glucocorticoid therapy. Clin Endocrinol (Oxf). 2019;90:3\u201314. https:\/\/doi.org\/10.1111\/CEN.13837.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2216_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/CLINEM\/DGAE822","volume":"00","author":"SD Steintorsdottir","year":"2024","unstructured":"Steintorsdottir SD, \u00d8ksnes M, J\u00f8rgensen AP, Husebye ES. Extended-release hydrocortisone formulations\u2014Is there a clinically meaningful benefit? J Clin Endocrinol Metab. 2024;00:1\u20138. https:\/\/doi.org\/10.1210\/CLINEM\/DGAE822.","journal-title":"J Clin Endocrinol Metab"},{"key":"2216_CR45","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S2213-8587(17)30398-4","volume":"6","author":"AM Isidori","year":"2018","unstructured":"Isidori AM, Venneri MA, Graziadio C, Simeoli C, Fiore D, Hasenmajer V, et\u00a0al. Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 2018;6:173\u201385. https:\/\/doi.org\/10.1016\/S2213-8587(17)30398-4.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2216_CR46","doi-asserted-by":"publisher","first-page":"e2063","DOI":"10.1210\/CLINEM\/DGAB051","volume":"106","author":"DP Merke","year":"2021","unstructured":"Merke DP, Mallappa A, Arlt W, Brac De La Perriere A, Lind\u00e9nHirschberg A, Juul A, et\u00a0al. Modified-release hydrocortisone in congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2021;106:e2063\u201377. https:\/\/doi.org\/10.1210\/CLINEM\/DGAB051.","journal-title":"J Clin Endocrinol Metab"},{"key":"2216_CR47","doi-asserted-by":"publisher","DOI":"10.1530\/EC-24-0150","author":"DA Rees","year":"2024","unstructured":"Rees DA, Merke DP, Arlt W, De La Perriere AB, Hirschberg AL, Juul A, et\u00a0al. Comparison of modified-release hydrocortisone capsules versus prednisolone in the treatment of congenital adrenal hyperplasia. Endocr Connect. 2024. https:\/\/doi.org\/10.1530\/EC-24-0150.","journal-title":"Endocr Connect"},{"key":"2216_CR48","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1210\/ER.2015-1080","volume":"38","author":"H Oster","year":"2017","unstructured":"Oster H, Challet E, Ott V, Arvat E, de Kloet ER, Dijk DJ, et\u00a0al. The functional and clinical significance of the 24-hour rhythm of circulating glucocorticoids. Endocr Rev. 2017;38:3\u201345. https:\/\/doi.org\/10.1210\/ER.2015-1080.","journal-title":"Endocr Rev"},{"key":"2216_CR49","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/NRN2914","volume":"11","author":"SL Lightman","year":"2010","unstructured":"Lightman SL, Conway-Campbell BL. The crucial role of pulsatile activity of the HPA axis for continuous dynamic equilibration. Nat Rev Neurosci. 2010;11:710\u20138. https:\/\/doi.org\/10.1038\/NRN2914.","journal-title":"Nat Rev Neurosci"},{"key":"2216_CR50","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.1210\/JC.2016-1916","volume":"101","author":"AA Nella","year":"2016","unstructured":"Nella AA, Mallappa A, Perritt AF, Gounden V, Kumar P, Sinaii N, et\u00a0al. A phase 2 study of continuous subcutaneous hydrocortisone infusion in adults with congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2016;101:4690\u20138. https:\/\/doi.org\/10.1210\/JC.2016-1916.","journal-title":"J Clin Endocrinol Metab"},{"key":"2216_CR51","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/JOIM.13721","volume":"295","author":"G Russell","year":"2023","unstructured":"Russell G, Kalafatakis K, Durant C, Marchant N, Thakrar J, Thirard R, et\u00a0al. Ultradian hydrocortisone replacement alters neuronal processing, emotional ambiguity, affect and fatigue in adrenal insufficiency: the PULSES trial. J Intern Med. 2023;295:51. https:\/\/doi.org\/10.1111\/JOIM.13721.","journal-title":"J Intern Med"},{"key":"2216_CR52","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/EJE-21-0794","volume":"186","author":"A Prete","year":"2021","unstructured":"Prete A, Auchus RJ, Ross RJ. Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia. Eur J Endocrinol. 2021;186:R1-14. https:\/\/doi.org\/10.1530\/EJE-21-0794.","journal-title":"Eur J Endocrinol"},{"key":"2216_CR53","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/0306-4530(95)00011-9","volume":"20","author":"EB De Souza","year":"1995","unstructured":"De Souza EB. Corticotropin-releasing factor receptors: physiology, pharmacology, biochemistry and role in central nervous system and immune disorders. Psychoneuroendocrinology. 1995;20:789\u2013819.","journal-title":"Psychoneuroendocrinology"},{"key":"2216_CR54","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1210\/JC.2015-3574","volume":"101","author":"AF Turcu","year":"2016","unstructured":"Turcu AF, Spencer-Segal JL, Farber RH, Luo R, Grigoriadis DE, Ramm CA, et\u00a0al. Single-dose study of a corticotropin-releasing factor receptor-1 antagonist in women with 21-hydroxylase deficiency. J Clin Endocrinol Metab. 2016;101:1174\u201380. https:\/\/doi.org\/10.1210\/JC.2015-3574.","journal-title":"J Clin Endocrinol Metab"},{"key":"2216_CR55","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1210\/CLINEM\/DGAB749","volume":"107","author":"RJ Auchus","year":"2022","unstructured":"Auchus RJ, Sarafoglou K, Fechner PY, Vogiatzi MG, Imel EA, Davis SM, et\u00a0al. Crinecerfont lowers elevated hormone markers in adults with 21-hydroxylase deficiency congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2022;107:801\u201312. https:\/\/doi.org\/10.1210\/CLINEM\/DGAB749.","journal-title":"J Clin Endocrinol Metab"},{"key":"2216_CR56","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1056\/NEJMOA2404656","volume":"391","author":"RJ Auchus","year":"2024","unstructured":"Auchus RJ, Hamidi O, Pivonello R, Bancos I, Russo G, Witchel SF, et\u00a0al. Phase 3 trial of crinecerfont in adult congenital adrenal hyperplasia. N Engl J Med. 2024;391:504\u201314. https:\/\/doi.org\/10.1056\/NEJMOA2404656.","journal-title":"N Engl J Med"},{"issue":"6","key":"2216_CR57","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMOA2404655","volume":"391","author":"K Sarafoglou","year":"2024","unstructured":"Sarafoglou K, Kim MS, Lodish M, Felner EI, Martinerie L, Nokoff NJ, et\u00a0al. Phase 3 trial of crinecerfont in pediatric congenital adrenal hyperplasia. N Engl J Med. 2024;391(6):493\u2013503. https:\/\/doi.org\/10.1056\/NEJMOA2404655.","journal-title":"N Engl J Med"},{"key":"2216_CR58","doi-asserted-by":"publisher","DOI":"10.1210\/CLINEM\/DGAB438","volume":"106","author":"K Sarafoglou","year":"2021","unstructured":"Sarafoglou K, Barnes CN, Huang M, Imel EA, Madu IJ, Merke DP, et\u00a0al. Tildacerfont in adults with classic congenital adrenal hyperplasia: results from two phase 2 studies. J Clin Endocrinol Metab. 2021;106: E4666\u201379. https:\/\/doi.org\/10.1210\/CLINEM\/DGAB438.","journal-title":"J Clin Endocrinol Metab"},{"key":"2216_CR59","unstructured":"Spruce biosciences announces topline results from CAHmelia-204 in adult CAH and CAHptain-205 in adult and pediatric CAH | Spruce Biosciences."},{"key":"2216_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/J.JPEDS.2014.01.011","author":"K Sarafoglou","year":"2014","unstructured":"Sarafoglou K, Addo OY, Turcotte L, Otten N, Wickremasinghe A, Pittock S, et\u00a0al. Impact of hydrocortisone on adult height in congenital adrenal hyperplasia-The Minnesota cohort. J Pediatr. 2014. https:\/\/doi.org\/10.1016\/J.JPEDS.2014.01.011.","journal-title":"J Pediatr"},{"key":"2216_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/CLINEM\/DGAE771","volume":"00","author":"H Al-Rayess","year":"2024","unstructured":"Al-Rayess H, Wiersma R, Turner LE, Palzer E, Mercado Munoz Y, Sarafoglou K. Anastrozole improves height outcomes in growing children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab. 2024;00:1\u201310. https:\/\/doi.org\/10.1210\/CLINEM\/DGAE771.","journal-title":"J Clin Endocrinol Metab"},{"key":"2216_CR62","doi-asserted-by":"publisher","DOI":"10.1210\/CLINEM\/DGAE824","author":"DP Merke","year":"2024","unstructured":"Merke DP, Mallappa A, Parker M, Sukin C, Kulkarni SE, Keil MF, et\u00a0al. Adult height following prepubertal treatment with antiandrogen, aromatase inhibitor, and reduced hydrocortisone in CAH. J Clin Endocrinol Metab. 2024. https:\/\/doi.org\/10.1210\/CLINEM\/DGAE824.","journal-title":"J Clin Endocrinol Metab"},{"key":"2216_CR63","doi-asserted-by":"publisher","first-page":"997","DOI":"10.4158\/EP-2019-0610","volume":"26","author":"W Xi","year":"2020","unstructured":"Xi W, Mao J, Li S, Zhao Y, Nie M, Yu B, et\u00a0al. Aromatase inhibitor increases the height of patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Pract. 2020;26:997\u20131002. https:\/\/doi.org\/10.4158\/EP-2019-0610.","journal-title":"Endocr Pract"},{"key":"2216_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/FENDO.2016.00101","author":"AJ Clark","year":"2016","unstructured":"Clark AJ, Forfar R, Hussain M, Jerman J, McIver E, Taylor D, et\u00a0al. ACTH antagonists. Front Endocrinol (Lausanne). 2016. https:\/\/doi.org\/10.3389\/FENDO.2016.00101.","journal-title":"Front Endocrinol (Lausanne)."},{"key":"2216_CR65","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/S11259-018-9737-X","volume":"42","author":"K Sanders","year":"2018","unstructured":"Sanders K, Mol JA, Kooistra HS, Galac S. Melanocortin 2 receptor antagonists in canine pituitary-dependent hypercortisolism: in vitro studies. Vet Res Commun. 2018;42:283. https:\/\/doi.org\/10.1007\/S11259-018-9737-X.","journal-title":"Vet Res Commun"},{"key":"2216_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/EN.2016-1455","volume":"158","author":"AL Feldhaus","year":"2017","unstructured":"Feldhaus AL, Anderson K, Dutzar B, Ojala E, McNeill PD, Fan P, et\u00a0al. ALD1613, a novel long-acting monoclonal antibody to control ACTH-driven pharmacology. Endocrinology. 2017;158:1\u20138. https:\/\/doi.org\/10.1210\/EN.2016-1455.","journal-title":"Endocrinology"},{"key":"2216_CR67","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1210\/EN.2019-00117","volume":"160","author":"AL Gehrand","year":"2019","unstructured":"Gehrand AL, Phillips J, Malott K, Raff H. A long-acting neutralizing monoclonal ACTH antibody blocks corticosterone and adrenal gene responses in neonatal rats. Endocrinology. 2019;160:1719\u201330. https:\/\/doi.org\/10.1210\/EN.2019-00117.","journal-title":"Endocrinology"},{"key":"2216_CR68","doi-asserted-by":"publisher","first-page":"bvae163.285","DOI":"10.1210\/JENDSO\/BVAE163.285","volume":"8","author":"U Srirangalingam","year":"2024","unstructured":"Srirangalingam U, Velusamy A, Binderup ML, Baker B, Flensburg MF, Boserup LP, et\u00a0al. 12484 safety and pharmacokinetics of anti-ACTH antibody Lu AG13909 in patients with classic congenital adrenal hyperplasia: phase 1 open-label, multiple-ascending-dose trial protocol. J Endocr Soc. 2024;8:bvae163.285. https:\/\/doi.org\/10.1210\/JENDSO\/BVAE163.285.","journal-title":"J Endocr Soc."},{"key":"2216_CR69","doi-asserted-by":"publisher","DOI":"10.1210\/JENDSO\/BVAE163.249","author":"R Joseph Auchus","year":"2024","unstructured":"Joseph Auchus R, James Trainer P, Jean Lucas K, Bruera D, Marko J, Ayala A, et\u00a0al. 12537 once daily oral atumelnant (CRN04894) induces rapid and profound reductions of androstenedione and 17-hydroxyprogesterone in participants with classical congenital adrenal hyperplasia: initial results from a 12-week, phase 2, open-label study. J Endocr Soc. 2024. https:\/\/doi.org\/10.1210\/JENDSO\/BVAE163.249.","journal-title":"J Endocr Soc."},{"key":"2216_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13287-024-04036-0","volume":"15","author":"D Kumar","year":"2024","unstructured":"Kumar D, Tanwar R. World\u2019s first: stem cell therapy reverses diabetes. Stem Cell Res Ther. 2024;15:1\u20133. https:\/\/doi.org\/10.1186\/S13287-024-04036-0.","journal-title":"Stem Cell Res Ther"},{"key":"2216_CR71","doi-asserted-by":"publisher","first-page":"6152","DOI":"10.1016\/j.cell.2024.09.004","volume":"187","author":"S Wang","year":"2024","unstructured":"Wang S, Du Y, Zhang B, Meng G, Liu Z, Liew SY, et\u00a0al. Transplantation of chemically induced pluripotent stem-cell-derived islets under abdominal anterior rectus sheath in a type 1 diabetes patient. Cell. 2024;187:6152-6164.e18. https:\/\/doi.org\/10.1016\/j.cell.2024.09.004.","journal-title":"Cell"},{"key":"2216_CR72","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1016\/J.DEVCEL.2022.10.010","volume":"57","author":"Y Sakata","year":"2022","unstructured":"Sakata Y, Cheng K, Mayama M, Seita Y, Detlefsen AJ, Mesaros CA, et\u00a0al. Reconstitution of human adrenocortical specification and steroidogenesis using induced pluripotent stem cells. Dev Cell. 2022;57:2566-2583.e8. https:\/\/doi.org\/10.1016\/J.DEVCEL.2022.10.010.","journal-title":"Dev Cell"},{"key":"2216_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/J.CRMETH.2023.100627","author":"G Ruiz-Babot","year":"2023","unstructured":"Ruiz-Babot G, Eceiza A, Abollo-Jim\u00e9nez F, Malyukov M, Carlone DL, Borges K, et\u00a0al. Generation of glucocorticoid-producing cells derived from human pluripotent stem cells. Cell Rep Methods. 2023. https:\/\/doi.org\/10.1016\/J.CRMETH.2023.100627.","journal-title":"Cell Rep Methods"},{"key":"2216_CR74","doi-asserted-by":"publisher","first-page":"601","DOI":"10.4158\/EP.13.6.601","volume":"13","author":"G Bahtiyar","year":"2007","unstructured":"Bahtiyar G, Weiss K, Sacerdote AS. Novel endocrine disrupter effects of classic and atypical antipsychotic agents and divalproex: induction of adrenal hyperandrogenism, reversible with metformin or rosiglitazone. Endocr Pract. 2007;13:601\u20138.","journal-title":"Endocr Pract"},{"key":"2216_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2010\/614107","volume":"2010","author":"RJ Auchus","year":"2010","unstructured":"Auchus RJ. Management of the adult with congenital adrenal hyperplasia. Int J Pediatr Endocrinol. 2010;2010:1\u20139. https:\/\/doi.org\/10.1155\/2010\/614107.","journal-title":"Int J Pediatr Endocrinol"},{"key":"2216_CR76","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/J.FERTNSTERT.2012.06.018","volume":"98","author":"V Bruni","year":"2012","unstructured":"Bruni V, Peruzzi E, Dei M, Nannini S, Seravalli V, Sisti G, et\u00a0al. Hepatotoxicity with low- and ultralow-dose flutamide: a surveillance study on 203 hyperandrogenic young females. Fertil Steril. 2012;98:1047\u201352. https:\/\/doi.org\/10.1016\/J.FERTNSTERT.2012.06.018.","journal-title":"Fertil Steril"},{"key":"2216_CR77","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1530\/EJE-19-0905","volume":"182","author":"C Wright","year":"2020","unstructured":"Wright C, O\u2019Day P, Alyamani M, Sharifi N, Auchus RJ. Abiraterone acetate treatment lowers 11-oxygenated androgens. Eur J Endocrinol. 2020;182:413\u201321. https:\/\/doi.org\/10.1530\/EJE-19-0905.","journal-title":"Eur J Endocrinol"},{"key":"2216_CR78","doi-asserted-by":"publisher","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","volume":"26","author":"G Attard","year":"2008","unstructured":"Attard G, Reid AHM, Yap TA, Raynaud F, Dowsett M, Settatree S, et\u00a0al. Phase i clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008;26:4563\u201371. https:\/\/doi.org\/10.1200\/JCO.2007.15.9749.","journal-title":"J Clin Oncol"},{"key":"2216_CR79","unstructured":"BridgeBio Pharma Reports Topline Results from Phase 1\/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH) - BridgeBio. URL: https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-toplineresults- from-phase-1-2-trial-of-investigational-gene-therapy-for-congenital-adrenal-hyperplasia-cah\/"},{"key":"2216_CR80","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1093\/EJENDO\/LVAE144","volume":"191","author":"CJ Kyle","year":"2024","unstructured":"Kyle CJ, Boyle LD, Nixon M, Homer NZM, Simpson JP, Rutter A, et\u00a0al. Proof of concept for a superior therapeutic index of corticosterone compared with hydrocortisone in patients with congenital adrenal hyperplasia. Eur J Endocrinol. 2024;191:535\u201344. https:\/\/doi.org\/10.1093\/EJENDO\/LVAE144.","journal-title":"Eur J Endocrinol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02216-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02216-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02216-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T14:34:05Z","timestamp":1763044445000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02216-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":80,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2216"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02216-7","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,2]]},"assertion":[{"value":"14 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"N.P.K. has received consultancy honoraria from Adrenas Therapeutics, Diurnal Ltd and Neurocrine Biosciences. N.K. chairs the CaHASE2 Study Steering Committee of the Society for Endocrinology, UK that received grant support for an investigator-initiated trial by Neurocrine Biosciences. J.J.T. and I.B. declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors contributed to the manuscript. Original draft preparation: Joseph J. Tonge. Writing, review, and editing: Joseph J. Tonge, Irina Bacila and Nils P. Krone. All authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}